Eli Lilly 2026 Guidance Signals Momentum In Obesity Care
Eli Lilly has forecast 2026 profit and revenue above Wall Street expectations, reinforcing how fast the obesity market is reshaping Big Pharma growth plans. The recent Eli Lilly 2026 Guidance reflects the company’s confidence in strong future performance. The company also beat estimates for fourth-quarter earnings, helped by strong demand for its injectable weight-loss and…...
Aspen APAC Divestment Unlocks R26.5 Billion For GLP-1 Focus
Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026.
Lilly Hits $1 Trillion Valuation with Weight-Loss Success
Eli Lilly hits $1 trillion valuation, marking a historic milestone in the pharmaceutical industry with successful weight-loss drugs.
Aspen Targets Mounjaro Expansion in Africa Following Approval
Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.
Aspen Boosted by Mounjaro: A New Era in Weight Loss
Aspen shares soar following the approval of Mounjaro for weight loss in South Africa. Discover the impact on obesity management.
Novo Nordisk Hiring Freeze After Wegovy Sales Decline
Novo Nordisk implements a hiring freeze as layoffs approach after Wegovy's success. Discover the impact on the pharmaceutical industry.
Ozempic and Mounjaro are reshaping South Africa’s health market
Understand the significance of Ozempic and Mounjaro in the evolving landscape of diabetes care and weight management in South Africa.
Lilly’s Orforglipron Shows Significant Weight Loss in Phase 3 Trial
Orforglipron can offer a new oral option for managing weight loss and blood sugar in type 2 diabetes treatment.
A decade of transformation in obesity treatment
ObesityWeek 2024 attracted unprecedented attention from Wall Street, highlighting obesity treatment's booming pharmaceutical industry.
As competition heats up, Novo Nordisk’s share price declines
Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.